Here is what can still fail the SLS trial when success seems "guaranteed"

Since SLS has a market cap of 1.7 billion , I'm allowing myself to show you my thoughts on it. I'm a university professor in biomedicine, suggesting that I have a rough idea of what I'm talking about. Even if I'm considered crazy for being here, please keep in mind that you are retarded , which makes us equal . Let's start with the enrollment data. There are a few official reports based on which we can have an educated guess about when the patients joined the trial. We know it started slowly with only 20ish